BGPT: Paper Review: MYC amplification and TERT expression in breast tumor progression

Explore by Goal

Quick Explanation Copied

Paper (2007) reviewed: MYC amplification & TERT expression in breast tumor progression

Key reported finding: MYC amplification (59%, 16/27) associates with early TNM (I–II), high genomic index, and high S-phase fraction, but shows no association with TERT immunostaining or TP53 mutation in this cohort .

Key reported finding: High TERT nuclear staining (grade 4; >50% nuclei) occurred in 58% (60/103) and associated with high genomic index, high S-phase fraction, and notably TP53 mutations, while showing no association with TNM stage .

Main interpretive tension: the authors argue MYC may be an early event while TERT relates to TP53 status, yet the study is cross-sectional and MYC–TERT linkage is statistically null; this weakens causal temporal claims .

Use the interactive plots below to inspect reported contingency patterns.

Long Explanation

Paper Review

“MYC amplification and TERT expression in breast tumor progression” (Cancer Genetics & Cytogenetics; DOI: 10.1016/j.cancergencyto.2007.04.002)

Cohorts: MYC FISH (n=27) and TERT IHC (n=103), with TP53 + genomic index + S-phase fraction

VISUALIZE FIRST: reported frequencies & co-variation

All plots are directly derived from the extracted counts in the provided full text.

Reported: MYC amplification in 16/27 (59%) .

Reported grade counts and definition: grade 4 corresponds to ≥50% nuclear staining .

Reported associations: MYC vs TNM I–II (P≤0.018), MYC vs genomic index >1.5 (P≤0.033), MYC vs S-phase >5% (P≤0.020). MYC vs TP53 mutation reported as non-significant .

Reported: grade-4 TERT associated with genomic index >1.5 (P=0.017), S-phase fraction >5% (P=0.056, borderline in the text), and TP53 mutation (P=0.030). No association reported with TNM stage .

EXPLAIN SECOND: what the study claims, and what the data actually support

Question	Reported relationship	Evidence strength (from study design)
Does MYC amplification mark early progression?	MYC amplification associated with TNM stages I–II (P=0.018) and with higher genomic index >1.5 and higher S-phase fraction >5%	Moderate: cross-sectional correlations in a small, selected FISH subset (n=27)
Is MYC amplification linked to TERT expression?	Null association reported between MYC amplification and TERT immunostaining in this dataset	Moderate–strong for “no association” within the measured categories, but weak for causal sequencing claims
Is TERT expression linked to genomic instability and TP53?	High TERT nuclear staining (grade 4) associates with genomic index >1.5, S-phase >5%, and TP53 mutations; no association with TNM stage	Moderate: larger TERT cohort (n=103) but still observational, and TERT is measured by IHC category rather than telomerase activity

Critical appraisal (skeptical, evidence-based)

1) Temporal claims are not directly testable here

The authors interpret the pattern as supporting “MYC as an early event” and TERT as linked to later/TP53-associated regulation. However, the MYC–TERT association in the measured categories is reported as absent, and the analysis is cross-sectional, so the temporal ordering is an inference, not a demonstrated sequence .

2) Selection bias: MYC FISH on a small, cytogenetically-selected subset

MYC amplification was assessed in only 27 tumors selected for chromosomal instability/complex changes. That selection plausibly inflates the observed frequency and shifts distributions of proliferation/genomic indices, potentially limiting generalizability to broader breast cancer populations .

3) Measurement/interpretation limitations for protein-level TERT

TERT is assessed by immunostaining grade categories (with a grade-4 cutoff at ≥50% nuclei). While useful clinically, IHC-grade discretization can mask within-grade biological variability and does not directly quantify telomerase enzymatic activity. This matters when relating TERT to proliferation/genomic instability and interpreting “TERT activation” claims .

4) Statistical considerations

Fisher’s exact test is reported, with two-sided P-values and OR/CIs for some associations. For small cell counts (e.g., MYC tested in only 27), OR estimates can be unstable even when P-values reach significance thresholds. The borderline association for TERT vs S-phase fraction (reported P=0.056) should be treated cautiously .

Blind spot worth highlighting: biological mechanistic leap

The discussion proposes that TP53 mutations imply functional p53 suppresses TERT transcription in breast tumors. But TP53 “mutation present” does not guarantee the functional status of p53 protein (e.g., dominant-negative vs loss-of-function vs rare contexts), nor does the study measure p53 protein activity or TERT promoter state. Thus, TP53–TERT association is supported as a correlation, but mechanism is suggestive rather than directly established in this paper .

Cross-check with newer mechanistic evidence on TERT regulation

A key mechanistic gap in the 2007 study is “how” telomerase/TERT is regulated beyond MYC and TP53. A later eLife study demonstrates that telomere length can modulate TERT expression via non-telomeric TRF2 and downstream epigenetic regulators (REST/EZH2 and H3K27me3), suggesting that TERT regulation can occur through telomere-length–linked chromatin partitioning rather than direct MYC→TERT coupling . This newer mechanism is compatible with the 2007 paper’s observation that MYC amplification is not statistically linked to TERT immunostaining in their cohort , but the mechanistic connection is not tested directly here.

What would most disprove/alter the paper’s main progression story?

Longitudinal or lineage-tracing evidence: show that MYC amplification does not precede the emergence of high-TERT states within the same tumor evolution trajectory, since temporal ordering is inferred rather than measured .
Orthogonal telomerase measures: demonstrate that IHC grade-4 TERT does not correspond to functional telomerase activity in this setting, which would weaken the meaning of “TERT activation” .
Mechanism-level measurements: show that TP53 mutation status does not mediate (or even track with) p53 activity at the TERT promoter, which would challenge the TP53→TERT mechanistic explanation for their correlation .

BGPT “science actions” you can run next

Author reviews on BGPT

Feedback:

Updated: May 01, 2026